CEMP Loses Big As D-Day Nears, AVXS Catches Investors' Eyes, No Respite For OPXA

Shares of Opexa Therapeutics Inc. (OPXA) were down over 20% on Wednesday, after the company announced a 40% reduction in the company's workforce in light of the failed phase 2b clinical trial of Tcelna in patients with secondary progressive multiple sclerosis, dubbed Abili-T.

from RTT - Biotech http://ift.tt/2fdW9ip
via IFTTT